Omalizumab in Severe Allergic Asthma: Indian perspective

Speciality: Pulmonary Medicine

Description:

A warm welcome to all the medical professionals in this interesting session on Omalizumab in Severe Allergic Asthma: Indian perspective.
Omalizumab, an anti-IgE monoclonal antibody, has emerged as a crucial treatment option for patients with severe allergic asthma in India, where the burden of asthma is significant. For individuals who remain uncontrolled despite using inhaled corticosteroids and long-acting beta-agonists, omalizumab offers a targeted approach by neutralizing IgE, a key molecule in allergic responses. This treatment has been shown to reduce asthma exacerbations, improve lung function, and enhance overall quality of life.
From an Indian perspective, omalizumab has been particularly beneficial in managing severe allergic asthma in a population that often faces challenges in accessing advanced care. Patients who previously experienced frequent hospitalizations and emergency visits have seen a dramatic improvement in symptom control and reduced healthcare utilization. Given the convenience of its subcutaneous administration, omalizumab also supports better adherence to treatment. As awareness and availability grow in India, it continues to provide a transformative solution for managing severe allergic asthma.
Therefore, get an overall knowledge of Omalizumab in Severe Allergic Asthma: Indian perspective. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars